Two New TB Vaccines Show 79% Efficacy in Major Study

India just took a giant leap forward in the fight against tuberculosis, and millions of children could benefit.

Two new vaccines developed by Indian pharmaceutical companies have shown remarkable effectiveness against TB in a major clinical study published in the British Medical Journal. The research validates years of work by scientists at Pune's Serum Institute of India and Cadila Pharmaceuticals, who developed vaccines that could finally protect teens and adults where the century-old BCG vaccine falls short.

The results are stunning. VPM1002 showed 79.5% effectiveness against extrapulmonary TB in adults aged 36 to 60. For children and adolescents aged 6 to 14, the vaccine demonstrated over 60% protection against all forms of TB, including the hard-to-diagnose extrapulmonary version that attacks organs beyond the lungs.

This matters enormously for India, which accounts for more than a quarter of global TB cases. About 22% of those cases are extrapulmonary TB, a particularly challenging form that affects lymph nodes, the spine, and abdominal organs. These cases are notoriously difficult to diagnose and treat, leading to high rates of long-term health problems.

The second vaccine, Immuvac, also performed impressively. It showed 66.3% efficacy against extrapulmonary TB in people with latent infections and over 60% protection for children aged 6 to 10.

What makes these vaccines special is their ability to prevent latent TB infections from becoming active disease. Both vaccines showed around 50 to 60% efficacy in stopping this progression, creating a crucial barrier against TB spread within families and communities.

The Ripple Effect

The study included household contacts of TB patients, the group at highest risk of infection. By protecting family members, especially children living with TB patients, these vaccines could break the cycle of transmission that keeps the disease circulating through generations.

The research team, led by Dr. Manjula Singh of the Indian Council of Medical Research and including prominent scientists like Dr. Randeep Guleria, designed the trial to reflect real-world conditions. They included participants with various health conditions and risk factors, making the results broadly applicable.

There's an important caveat. Neither vaccine protected underweight children and adults effectively, highlighting that vaccination alone isn't enough. Dr. Anant Phadke, a public healthcare advocate, emphasized that improving nutrition and housing must remain central to TB elimination efforts.

The vaccines work best as part of a comprehensive strategy combining better living conditions, early detection, and immunization. For well-nourished household contacts of TB patients, particularly children, these vaccines offer protection that simply didn't exist before.

India now has homegrown tools that could reshape its battle against a disease that has plagued humanity for millennia, and the breakthrough came from Indian scientists working to solve an Indian problem.